Jaqueline C. Fernandes

Ribeirao Preto, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The murine Irs1 knockout model, generated by the spontaneous Irs1S57X mutation in homozygosity, exhibits high embryonic lethality, limiting studies of adult hematopoiesis.

The murine Irs1 knockout model, generated by the spontaneous Irs1S57X mutation in homozygosity, exhibits high embryonic lethality, limiting studies of adult hematopoiesis.

Journal: Hematology, transfusion and cell therapy

Published: January 09, 2026

Pharmacokinetic analysis of 25 mg estradiol subcutaneous bioabsorbable implant in postmenopausal women (CLARA STUDY).

Pharmacokinetic analysis of 25 mg estradiol subcutaneous bioabsorbable implant in postmenopausal women (CLARA STUDY).

Journal: Menopause (New York, N.Y.)

Published: April 28, 2025

Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells.

Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells.

Journal: Toxicology in vitro : an international journal published in association with BIBRA

Published: March 16, 2022

Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.

Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.

Journal: Investigational new drugs

Published: October 29, 2021

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.

Journal: Investigational new drugs

Published: August 24, 2020

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells.

Journal: Signal transduction and targeted therapy

Published: March 22, 2019

IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.

IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.

Journal: Cancer letters

Published: January 21, 2019

Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis.

Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis.

Journal: Clinics (Sao Paulo, Brazil)

Published: January 10, 2018

Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells.

Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells.

Journal: Heliyon

Published: June 02, 2017

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Journal: Cell death & disease

Published: May 02, 2017

IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.

IRS1/β-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.

Journal: Journal of cellular biochemistry

Published: August 23, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026